Vita Therapeutics Raises $32 Million In Oversubscribed Series A Financing Led By Cambrian Biopharma To Advance The Development Of Therapies To Treat Muscular Dystrophies
Vita Therapeutics Raises $32 Million In Oversubscribed Series A Financing Led By Cambrian Biopharma To Advance The Development Of Therapies To Treat Muscular Dystrophies
06/23/21, 11:09 AM
Location
baltimoreMoney raised
$32 million
Round Type
series a
Vita Therapeutics, a cell engineering company harnessing the power of genetics to develop cellular therapies that follow an autologous and universal hypoimmunogenic approach, today announced the completion of an oversubscribed $32 million Series A. The financing was led by Cambrian Biopharma with participation from Kiwoom Bio, SCM Life Sciences, and Early Light Ventures.
Company Info
Location
baltimore, maryland, united states
Additional Info
Vita Therapeutics, a Cambrian Biopharma affiliate, is a cell engineering company harnessing the power of genetics to develop cellular therapies that follow a dual manufacturing strategy, first beginning autologously before moving to a universal hypoimmunogenic cell line. Vita was originally founded out of the labs of Dr. Gabsang Lee and Dr. Kathryn Wagner at Johns Hopkins University and the Kennedy Krieger Institute in 2019 by Douglas Falk, M.S. and Peter Andersen, PhD. The company utilizes induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace those that are defective in patients. We are currently working to progress our lead therapeutic, VTA-100, for the treatment of limb-girdle muscular dystrophy (LGMD), into clinical trials. For more information and important updates, please visit www.vitatx.com or follow us on Twitter @Vita_Tx and LinkedIn.